• The funds will be used to accelerate Apricity’s growth in the UK and expand its geographic footprint
  • In 2022, Apricity doubled revenue, acquired women’s health app Woom and increased its B2B offering by signing up employee benefits providers such as AXA and Reward Gateway
  • Apricity is a pioneer in new technologies to transform fertility care, such as 3D reconstruction for embryo selection, and boasts a 46% success rate* per cycle (vs. 31% average for traditional clinics)

LONDON, UK, Monday, September 5, 2022: Appreciationthe UK’s leading virtual infertility clinic, has raised €17 million in a Series B round led by MTIPa Swiss investor in the field of medical technology, with the participation of a specialized consumer fund from Barcelona Iris Ventures.

The new funds will be used to accelerate Apricity’s growth in the UK, geographic expansion (to Spain by the end of the year, followed by Germany and Italy) and further technology development as the company continues its mission to become a leading fertility manufacturer. player in Europe. This includes expanding home services to include home ultrasound scans in select areas.

Launched in the UK in 2018 and initially incubated by Kamet Ventures, Apricity heralds a new approach to reproductive medicine – combining fertility care with technology to increase chances of conception and outperform traditional clinics while offering a smoother patient experience. The service helps at every stage of fertility treatment and provides ongoing personalized support through its app. With one in six couples struggling to conceive, Apricity boasts a 46% success rate per cycle* compared to the UK average of 31%. Meanwhile, the global fertility market is projected to reach $26 billion by 2027.

Apricity has seen rapid growth in the past year, more than doubling revenue and customer growth. In May this year, it acquired Madrid-based period tracking app Woom and has signed contracts with major corporate clients who use Apricity as part of their employee benefits, including tech giants, major banks, as well as leading UK employee benefits providers, AXA and Reward Gateway. The B2B offering now generates more than a third of its revenue.

Apricity’s technical team recently developed first-of-its-kind AI algorithms that determine the most appropriate fertility treatment for patients and then determine the best embryo to select using 3D reconstruction. Apricity is the first company to develop 3D embryo reconstruction technology to aid in fertility treatment.

Caroline Noublanche, founder and CEO of Apricitysaid: “MTIP’s deep-rooted understanding of the healthcare landscape, combined with Iris Ventures’ experience in the consumer space, will be invaluable as Apricity enters its next phase of growth and we expand into more regions. We look forward to supporting more women and couples across Europe who are trying to conceive and can now look forward to a better, less stressful alternative.”

Christoph Kausch, managing partner of MTIPsaid: “The virtual business model has really gained traction throughout the healthcare industry, and Apricity was one of its pioneers. Rather than focusing on just one part of the fertility journey, Apricity is leveraging cutting-edge technology to transform the end-to-end experience for patients and has achieved incredibly strong traction as a result.”

Mark Dietrich, who serves on the Board of Directors on behalf of MTIP, adds: “Fertility technology is one of the most important areas of innovation in healthcare, and we are excited to support Apricity as it leads the industry to new heights.”

Montse Suarez, founder and managing partner of Iris Venturessaid: “At Iris Ventures, we are driven by the search for businesses that put the needs of today’s consumer at the center of their mission. Without a doubt, Apricity is a leader in its field, using patient-centered technology to make a real impact in the lives of fertility patients by providing high-quality care when and where patients need it most. It is only a matter of time before Apricity’s great success in the UK is exported to other European markets such as Spain and we are proud to join Caroline and the entire Apricity team in their mission to redefine fertility care.”


*Clinical pregnancy rates (per embryo transfer) for all egg sources and all ages, period 2021. See https://www.apricity.life/ivf-success-rate

About Aprichnost

Apricity is a virtual fertility clinic that has reimagined the fertility journey by combining technology and artificial intelligence with personalized care and medical expertise. Its digital solution is designed to improve the fertility experience and maximize the chances of conception. It achieves this by providing access to world-class fertility consultants and fully customized treatment for patients, all easily navigated through a mobile app. Apricity’s mission is to help you create a life – and live yours.

For more information visit https://www.apricity.life/

About MTIP

MTIP is a leading Swiss company that invests in European medical technology companies. We leverage our deep sector expertise to help founders grow successful and sustainable digital healthcare businesses. At MTIP, we are driven by a mission to empower innovative healthcare technologies with the potential to impact and improve the lives of millions of people.

For more information visit: https://www.mtip.ch/

About IRIS Ventures

IRIS Ventures is an advisor to IRIS Fund I FCRE, a growth equity fund focused on European and American consumer-oriented brands and technology solutions that create healthier, happier and more convenient lives. IRIS Ventures operates in Barcelona, ​​London and New York.

For more information visit: https://weareiris.com/

Digiqole Advertisement

Apricity Fertility (t/a Apricity) secures £14.65 million Series B investment led by MTIP

Previous articleАлівія Уайлд на прэм’еры фільма “Не хвалюйся, мілая” дэманструе пышную сукенку ў салатавым сукенцы
Next articleA defector from North Korea uses balloons to deliver Covid aid and leaflets into the country